Literature DB >> 25741171

Primary gastrointestinal stromal tumor of the liver treated with sequential therapy.

Xian-Ke Lin1, Qing Zhang1, Wei-Li Yang1, Chun-Hui Shou1, Xiao-Sun Liu1, Jian-Yi Sun1, Ji-Ren Yu1.   

Abstract

A 67-year-old female presented with a primary hepatic gastrointestinal stromal tumor that was detected by computed tomography and diagnosed based on histopathological and genetic analyses. The tumor was microscopically composed of spindle cells and epithelioid cells, and immunohistochemistry results showed positive staining for CD117 and CD34 expression. A genetic analysis revealed a heterozygous point mutation and deletion in exon 11 of c-KIT. After an R0 resection, imatinib mesylate was administered for 1 year until its use was discontinued due to severe side effects. Two years after the original operation, the tumor recurred in the residual liver and was completely resected again. Imatinib mesylate was administered for 2 years until it was replaced by sunitinib malate because of disease progression. The patient has survived for 53 mo after undergoing a sequential therapy consisting of surgical excision, imatinib and sunitinib.

Entities:  

Keywords:  Diagnosis and treatment; Gastrointestinal stromal tumor; Liver; Sequential therapy; Tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2015        PMID: 25741171      PMCID: PMC4342940          DOI: 10.3748/wjg.v21.i8.2573

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

1.  Stromal tumor of the gallbladder with phenotype of interstitial cells of Cajal: a previously unrecognized neoplasm.

Authors:  C Ortiz-Hidalgo; B de Leon Bojorge; J Albores-Saavedra
Journal:  Am J Surg Pathol       Date:  2000-10       Impact factor: 6.394

2.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Authors:  George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

3.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

Authors:  L G Kindblom; H E Remotti; F Aldenborg; J M Meis-Kindblom
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 4.  Gastrointestinal stromal tumors: recent advances in understanding of their biology.

Authors:  M Miettinen; M Sarlomo-Rikala; J Lasota
Journal:  Hum Pathol       Date:  1999-10       Impact factor: 3.466

5.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Authors:  Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Jörg T Hartmann; Daniel Pink; Jochen Schütte; Giuliano Ramadori; Peter Hohenberger; Justus Duyster; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Maarit Sarlomo-Rikala; Bengt Nilsson; Harri Sihto; Odd R Monge; Petri Bono; Raija Kallio; Aki Vehtari; Mika Leinonen; Thor Alvegård; Peter Reichardt
Journal:  JAMA       Date:  2012-03-28       Impact factor: 56.272

6.  Interstitial cells of Cajal in pancreas.

Authors:  L M Popescu; M E Hinescu; N Ionescu; Sanda M Ciontea; D Cretoiu; Carmen Ardelean
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

7.  Gastrointestinal stromal tumor of the uterus: a case report with genetic analyses of c-kit and PDGFRA genes.

Authors:  Tadashi Terada
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

Review 8.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  Primary malignant gastrointestinal stromal tumor of the liver.

Authors:  Xuejiao Hu; Jameson Forster; Ivan Damjanov
Journal:  Arch Pathol Lab Med       Date:  2003-12       Impact factor: 5.534

10.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

Authors:  Heikki Joensuu
Journal:  Hum Pathol       Date:  2008-10       Impact factor: 3.466

View more
  5 in total

Review 1.  Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

2.  A case of primary hepatic stromal tumour misdiagnosed as a liver cyst.

Authors:  Fei Liu; Si-Hua Wu; Qiang-Qiang Sun; Sheng-Hai Liu; De-Fa Hou
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.573

3.  Clinicopathological feature and prognosis of primary hepatic gastrointestinal stromal tumor.

Authors:  Zhen Liu; Yangzi Tian; Shushang Liu; Guanghui Xu; Man Guo; Xiao Lian; Daiming Fan; Hongwei Zhang; Fan Feng
Journal:  Cancer Med       Date:  2016-08-03       Impact factor: 4.452

4.  Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion: A case report and systematic literature review.

Authors:  Liangliang Xu; Ming Zhang; Mingqing Xu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 5.  Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors.

Authors:  Xiao-Hui Qian; Ying-Cai Yan; Bing-Qiang Gao; Wei-Lin Wang
Journal:  World J Gastroenterol       Date:  2020-10-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.